Translate Bio, Inc. (TBIO)
$37.36
0.00 (0.00%)
Rating:
Recommendation:
-
| Symbol | TBIO |
|---|---|
| Price | $37.36 |
| Beta | 0.970 |
| Volume Avg. | 2.91M |
| Market Cap | 2.811B |
| Shares () | - |
| 52 Week Range | 12.5-37.985 |
| 1y Target Est | - |
| DCF Unlevered | TBIO DCF -> | |
|---|---|---|
| DCF Levered | TBIO LDCF -> | |
| ROE | 10.62% | Buy |
| ROA | 4.47% | Neutral |
| Operating Margin | - | |
| Debt / Equity | 119.29% | Buy |
| P/E | - | |
| P/B | 6.81 | Strong Buy |
Latest TBIO news
About
Download (Excel)Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. was founded in 2011 and is headquartered in Lexington, Massachusetts.